MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-05-2024
Nektar Therapeutics Cash Conversion Cycle 2011-2026 | NKTR
Annual Cash Conversion Cycle Nektar Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82 | 160 | 104 | -35.4 | 5.02 | 95.9 | 77 | 135 | 128 | 138 | 46.6 | 211 | 186 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 211 | -35.4 | 102 |
Quarterly Cash Conversion Cycle Nektar Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 148 | - | 173 | 77.1 | -9.3 | 29.7 | 32.4 | 6.72 | 5.99 | -35.6 | -92.3 | -0.91 | -6.72 | 24.6 | 121 | 132 | 198 | 95 | 137 | 60.4 | 98.6 | 73.6 | 144 | 38.2 | 39.4 | 43.7 | 27.6 | 46.2 | 30.4 | 80.3 | 9.88 | 16.8 | 2.48 | 11.5 | 13.5 | 6.53 | 3.34 | 6.01 | 15.9 | 25.1 | 28.8 | 22.4 | 27.3 | 28.6 | 16.6 | 26 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 198 | -92.3 | 44 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B |  USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.74 | 3.6 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-6 K | $ 3.36 | 0.86 % | $ 1.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Agios Pharmaceuticals
AGIO
|
735 | $ 29.16 | -3.54 % | $ 1.69 B | USA |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Завод ДИОД
DIOD
|
-32.7 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-15.9 | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Alector
ALEC
|
-13.8 | $ 2.19 | -9.77 % | $ 226 M | USA |
 |
Altimmune
ALT
|
15.1 K | $ 4.21 | -2.32 % | $ 299 M | USA |
 |
Teligent, Inc.
TLGT
|
120 | - | -13.85 % | $ 16.1 M | USA |
 |
Evogene Ltd.
EVGN
|
-32.5 | $ 0.84 | -4.24 % | $ 27.9 M | Israel |
 |
Viela Bio, Inc.
VIE
|
139 | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
157 | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
AbbVie
ABBV
|
284 | $ 233.57 | 0.64 % | $ 413 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
254 | - | - | $ 8.14 B | USA |
 |
AIM ImmunoTech
AIM
|
46 | $ 0.8 | -11.6 % | $ 38.5 M | USA |
 |
Aptorum Group Limited
APM
|
-400 | $ 0.83 | 5.37 % | $ 4.53 M | China |
 |
Apellis Pharmaceuticals
APLS
|
115 | $ 20.67 | -1.38 % | $ 2.61 B | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
128 | - | -7.31 % | $ 49 M | USA |